At March’s online “Racjonalny Inwestor” conference hosted by StockWatch.pl, our CEO, Wojciech Kula, joined a panel discussion on a key question: how do clinical trial strategies affect a biotech company’s investment appeal?
Wojciech shared the stage with experts from Noble Securities, Navigator Capital, and Bioceltix, discussing how strong clinical results and transparent trial execution build investor confidence.
The session, open and free to all investors, took place on October 15 and underscored the message: in today’s market, robust scientific evidence isn’t just a regulatory milestone—it’s a competitive advantage.
Explore why a well-designed, efficiently run clinical program is among the most powerful tools for enhancing market perception and supporting long-term growth. Watch the recording of the panel here (in Polish).
Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…
Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
Copyright @ 2025 Axcellant